Arix Bioscience Plc Director/PDMR Shareholding (2304I)
01 Dezembro 2022 - 4:45AM
UK Regulatory
TIDMARIX
RNS Number : 2304I
Arix Bioscience Plc
01 December 2022
Arix Bioscience plc
("Company")
PDMR notification & Director Shareholding
The Company announces the annual award of nil cost options to
CEO Robert Lyne, which are subject to performance conditions over a
three-year assessment period from 1 January 2022 to 31 December
2024 in accordance with the Company's Executive Incentive Plan
("EIP") as disclosed in the Company's Remuneration Policy
("Policy"). Vested Shares are subject to a further two year holding
period, as set out in the Policy.
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Robert Lyne
------------------------------------------- -------------------------------------------------------
Reason for the notification
2
----------------------------------------------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------------------------- -------------------------------------------------------
b) Initial notification Initial Notification
/Amendment
------------------------------------------- -------------------------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------------------------------
a) Name Arix Bioscience plc
------------------------------------------- -------------------------------------------------------
b) LEI 213800OVT3AHQCXNIX43
------------------------------------------- -------------------------------------------------------
Details of the transaction(s): section to be repeated for (i)
4 each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
----------------------------------------------------------------------------------------------------
a) Description of the Arix Bioscience plc Ordinary shares of 0.001
financial instrument, pence each
type of instrument
Identification code GB00BD045071
b) Nature of the transaction Award of nil-cost options under the Arix
Bioscience plc Executive Incentive Plan ("EIP")
---- ------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
------------------------------------------- ------------------------- -------------------------
Nil 636,792
-------------------------------------------------------------------------- -------------------------
d) Aggregated information
- Aggregated volume N/A (Single Transaction)
- Price N/A (Single Transaction)
e) Date of the transaction 30 November 2022
f) Place of the transaction Outside a trading venue
------------------------------------------- -------------------------------------------------------
For further information please contact:
Kin Company Secretarial Limited, Company Secretary
+44 20 8819 6486
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHDFLBBLLLXFBQ
(END) Dow Jones Newswires
December 01, 2022 02:45 ET (07:45 GMT)
Arix Bioscience (LSE:ARIX)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Arix Bioscience (LSE:ARIX)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025